"Oxford Vaccine" is one of the best candidates in the global vaccine race ... Where has it arrived?

Clinical trials of the third stage of the Oxford vaccine are being conducted in research facilities across the United Kingdom, the United States, Brazil and South Africa. Trials are also expected to begin next week in India, in partnership with the Serum Institute of India, according to the "Times of India" website.

The Oxford-supported vaccine, called AZD-12222, was one of the first vaccines to enter the human trial stage, as well as start trials in the late stages. It is also the vaccine that the World Health Organization found "the safest" so far in its pre-development stage.

Scientists have made the latest development using a non-replicating virus strain, and researchers hope to see the end of clinical trials by November or early December.

The Oxford researchers also signed an agreement with Mexico and Argentine authorities to expand production in the first quarter of 2021.

Adar Punwala, CEO of the Serum Institute in India, announced the availability of the vaccine to the Indian public this year.

In a recent interview with a media outlet, he said: "We will start trials in less than two weeks. The trial is in partnership with ICMR. We will start manufacturing vaccines by the end of August."

According to the proposals, the vaccine, which will be sold and marketed under the name "Coffeeshield" in India, will include candidates from a healthy age group.

India is recruiting 1,600 people over the age of 18 to participate in early trials, which will now spread across 17 locations, will include centers such as All India Institute of Medical Sciences, Delhi, Rajendra Memorial Research Institute of Medical (RMRIMS), Graduate Institute of Medical Education and Research in Chandigarh , AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, and JSS Academy of Higher Education and Research in Mysore.

The recent Oxford announcement may make it a little difficult for the world to get a vaccine early but it makes it slightly safer than others, as the early Russian vaccine launch, for example, was marred by controversy and safety concerns.

 The University of Oxford has also signed agreements with vaccine makers and global vaccine consortia. The World Health Organization has also requested major vaccine makers in the race to be part of its global COVAX vaccine alliance to ensure equitable dose distribution to the public.

The Serum Institute of India (SII) will also produce millions of doses for the company. The Serum Institute will also receive nearly $ 150 million in funding from the Bill and Melinda Gates Foundation to develop low-cost, readily available dosages. Funding will be directed through GAVI, the International Vaccine Alliance, and the vaccine product will help overcome problems related to marketing, production, and pricing at a global level.